Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

A new jab which allows cancer patients to be treated with just one injection is set to be rolled out by the NHS for 15 different types of the disease. Patients will be able to receive the ...

a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the breaks in immune response and strongly activating T and NK cells in ...